亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

隨州市紅旗化工有限公司  

醫藥原料醫藥中間體原料藥

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:閆先生
  • 電話:0722-3257386
  • 傳真:0722-3257381
  • QQ:1374834438
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 西替利嗪 CAS號: 83881-51-0
西替利嗪 CAS號: 83881-51-0
單價 面議對比
詢價 暫無
發貨 湖北隨州市付款后3天內
型號 83881-51-0
過期 長期有效
更新 2020-06-18 10:08
 
詳細信息
 西替利嗪
CAS號: 83881-51-0
中文同義詞: 西替利嗪;賽特贊;西替立嗪;仙特敏;2-[2-[4-[(4-氯苯基)苯甲基]-1-哌嗪基]乙氧基]乙酸;[2-[4-[(4-氯苯基)苯基甲基]-1-哌嗪基]乙氧基]乙酸
英文名稱: Cetirizine
英文同義詞: (2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-aceticaci;(2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)aceticacid;CETIRIZINE;(2-(4-[(4-CHLORO-PHENYL)-PHENYL-METHYL]-PIPERAZIN-1-YL)-ETHOXY)-ACETIC ACID;Cetirizine Hydrochloride BP;Cetirizine (Cetrizine) Di HCl;CERTIRIZINE 2HCL;CETIRIZINE IMPURITY A(RS)-1-[(4-CHLOROPHENYL)PHENYLMETHYL]PIPERAZINE EPC(CRM STANDARD)
分子式: C21H25ClN2O3
分子量: 388.89
熔點:110-115°C
水溶性:101 mg/L
標準;企業標準
含量:≥99.0%
性狀;白色或類白色粉末
用途:抗變態反應藥,有長效的選擇性和強的H1受體活性,而無鎮靜副作用。用于呼吸系統、皮膚和眼的過敏性疾病,包括慢性特發性蕁麻疹、常年性變應性鼻炎、枯草熱、輕微的鎮靜作用或口腔黏膜干燥等。
包裝;1kg/鋁箔袋
4500/kg
©2025 隨州市紅旗化工有限公司 版權所有   技術支持:化工網   訪問量:31441  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |